Association between CD133, CD44, and nestin expression and prognostic factors in high-grade meningiomas.

Association between CD133, CD44, and nestin expression and prognostic factors in high-grade meningiomas.

World Neurosurg. 2018 Dec 26;:

Authors: Kamamoto D, Saga I, Ohara K, Yoshida K, Sasaki H

Abstract
BACKGROUND: Meningioma is the most common primary brain tumor, which is graded I, II or III based on the World Health Organization (WHO) classification of central nervous system (CNS) tumors. Meningiomas, especially those classified as grade II-III, have an aggressive history and a high recurrence rate. Cancer stem cells (CSCs) represent a small subset of tumor cells and are considered to be involved in tumor initiation, growth, or recurrence. To date, CSCs of meningioma are not well established.
METHODS: We assessed 51 grade II/III meningiomas on immunohistochemistry to determine if there was a correlation with prognosis by investigating CD133, CD44 and nestin expression representative of CSC markers, age, gender, initial WHO tumor grade, Simpson grade, and adjuvant radiation therapy.
RESULTS: The median overall survival (OS) was 7.1 years, and the median progression-free survival (PFS) was 1.8 years. Univariate analysis using Cox proportional hazards regression revealed a negative correlation between CD133 and nestin expression and PFS (p = 0.0176 and 0.0138, respectively), and a high expression of CD44 demonstrated a tendency toward shorter PFS (p = 0.0563) as did initial WHO grade and Simpson grade on the initial operation (p = 0.0166 and 0.0333, respectively). Multivariate analysis showed relevance between CD133 and nestin and PFS.
CONCLUSIONS: CD133, nestin, initial WHO grade and Simpson grade were associated with PFS in grade II/III meningioma, which may suggest that these molecules are representative of CSCs in meningioma regarding the aspect of clinical course.

PMID: 30593958 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader http://bit.ly/2EVVq2M